Urothelial carcinoma is the most common type of bladder cancer, comprising more than 90% of the cases in industrialized countries. It is the 10th most common cancer worldwide and is reported to have nearly 4 times higher prevalence in men than in women. Studies indicate that metastatic urothelial carcinoma shows an overall poor prognosis with limited long-term survival rates, reflecting the critical need for more effective treatment options.
The Urothelial Carcinoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into urothelial carcinoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for urothelial carcinoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The urothelial carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from urothelial carcinoma.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to urothelial carcinoma.
Urothelial carcinoma or transitional carcinoma originates in the urothelium, the tissue that lines parts of the urinary system. It accounts for 90% and 7% of all cases of bladder cancer and kidney cancer, respectively. High-grade urothelial carcinoma often comes back even after treatment and may spread into the bladder’s muscle layer. On the other hand, low-grade urothelial carcinoma may be recurrent but the chances of it spreading into the muscle layer of the bladder are rare.
Common treatments for urothelial cancer include immunotherapy, targeted therapy, chemotherapy, and surgery, among others. In 2023, a two-drug combination of enfortumab vedotin and pembrolizumab (EV/pembro) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial bladder cancer. With the growing focus on immunotherapies and drugs targeting specific molecular pathways, the pipeline for urothelial cancer is poised for robust growth and innovation in the coming years. Additionally, the continued development of antibody-drug conjugates (ADCs) and combination regimens are expected to bring further advancements in the pipeline.
This section of the report covers the analysis of urothelial carcinoma drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for urothelial carcinoma. There are around 234 drugs in phase II of urothelial carcinoma.
The drug molecule categories covered under urothelial carcinoma pipeline analysis include immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), chemotherapeutic agents, PARP inhibitors, and tyrosine kinase inhibitors (TKIs). These drug classes comprise the major categories of therapies being developed for urothelial carcinoma. The choice of treatment varies depending on the specific type of patient population and the stage of the disease.
The EMR report for the urothelial carcinoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in urothelial carcinoma clinical trials:
Leading drugs in the pipeline are as follows:
Sponsored by UroGen Pharma Ltd., UGN-102 is currently involved in a Phase 3 multicenter study that will assess its efficacy and safety profile as a primary chemoablative therapy in non-muscle-invasive patients.
Bristol-Myers Squibb is sponsoring a Phase 3 clinical trial in which this drug is investigated for i...
Ipilimumab + nivolumab is in a Phase 2 study to evaluate the response of this induction therapy foll...
Currently, in Phase 1 of a multi-center, dose escalation and dose expansion study, the oral small mo...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Urothelial Carcinoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for urothelial carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within urothelial carcinoma pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Datasheet
USD 2,199
USD 1,899
tax inclusive*
Single User License
One User
USD 2,749
USD 2,299
tax inclusive*
Five User License
Five Users
USD 3,849
USD 3,299
tax inclusive*
Corporate License
Unlimited Users
USD 4,949
USD 4,199
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share